From Idea to Injection: How Spinraza Came to Be - SMA News Today
EMA opinion on broad-label approval for Spinraza – TreatSMA
Progress on Early Access Programme of Spinraza – TreatSMA
Buy Spinraza (Nusinersen) Online • Price & Costs | TheSocialMedwork
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
Farmalisa - Spinraza is a medicine used to treat 5q spinal muscular atrophy (SMA), a genetic disease that causes weakness and wasting of the muscles including the lung muscles. The disease is
Roche's low-price Evrysdi will take 'meaningful' SMA share from Biogen's Spinraza: analyst | FiercePharma
Biogen's blockbuster rare disease drug could be in trouble
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
Spinraza (PF) intrathecal: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
Spinraza®: coverage for all SMA type 1,2,3 patients - Institut de Myologie
NHS labels Spinraza deal “one of the most comprehensive in the world”
Official HCP Homepage | SPINRAZA® (nusinersen) | HCP
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
Novartis' £1.79M gene therapy Zolgensma scores cost watchdog's backing, threatening Biogen's Spinraza | FiercePharma
Spinraza™ represents the first FDA-approved drug for the treatment for... | Download Scientific Diagram
NHS to use world's most expensive drug to treat spinal muscular atrophy | NHS | The Guardian
First treatment for 5q spinal muscular atrophy approved by EU
NHS to use world's most expensive drug to treat spinal muscular atrophy | NHS | The Guardian
Spinraza in the UK ‒ questions and answers – TreatSMA
Biogen secures extended access agreement for Spinraza
Spinraza - FDA prescribing information, side effects and uses
What is Spinraza? Uses, Side Effects & More | TheSocialMedwork
A potential side effect added to Spinraza label – TreatSMA
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
Biogen bounces back with Spinraza early treatment data - PMLiVE
HSE to consider funding Spinraza as NHS approves muscle-wasting therapy
